Loading
ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems.
Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.89, clinical 0.81).
In plain words · ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression.
No product in this corpus aims at ADRA2A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRA2A: RNA tissue enhanced (adipose tissue 47 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ADRA2A tissue; Open Targets ENSG00000150594 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Kobilka B.K. et al, Science, 1987, "Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor". Source.
Sources: HGNC HGNC:281 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P08913 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000150594 (association with cancer (MONDO_0004992) 0.52; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.51 (GraphQL API, CC0))
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity. The rank order of potency for agonists of ADRA2A is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol. Location: Cell membrane (UniProt). Locus 10q25.2 (HGNC).
RNA: tissue enhanced (adipose tissue 47 nTPM), detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Pancreatic Adenocarcinoma 24 pTPM.
No cancer sample stained medium or high.
HPA ADRA2A tissue · HPA ADRA2A pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ADRA2A" OR ABSTRACT:"ADRA2A" OR TITLE:"adrenoceptor alpha 2A" OR ABSTRACT:"adrenoceptor alpha 2A" OR TITLE:"Alpha-2A adrenergic receptor" OR ABSTRACT:"Alpha-2A adrenergic receptor" OR TITLE:"ADRAR" OR ABSTRACT:"ADRAR" OR TITLE:"ADRA2" OR ABSTRACT:"ADRA2" OR TITLE:"ADRA2R" OR ABSTRACT:"ADRA2R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADRA2A, not a curated reading list.